ATH 33.3% 0.4¢ alterity therapeutics limited

Colin Masters poster session AAIC 2016, page-7

  1. 4 Posts.
    Here are the actual conclusions from the Masters' poster session:

    Conclusions: There was no significant difference between PBT2 and controls at 12-months, likely due to the large individual variances over a relatively small number of subjects. PBT2 was associated with significant PiB-PET SUVR decline in the double-blind phase and a stabilization of SUVR in the open-label phase. From this exploratory study, we have learned that the entry criterion of SUVR should have been set at ≥1.4 and <2.0, where Aβ accumulation follows a linear trajectory; and that subjects who withdrew from this type of study have much higher SUVRs, which if not taken into account, could distort the final results. Because of large individual variations in SUVR, future studies of PBT2 will require much larger numbers of subjects (n>90 per arm) over a longer period of time.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.4¢
Change
0.001(33.3%)
Mkt cap ! $21.28M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $9.838K 3.277M

Buyers (Bids)

No. Vol. Price($)
75 100044686 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 157644647 64
View Market Depth
Last trade - 16.10pm 12/11/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.